Quinnova launches Salvax in USA

12 January 2009

The USA's Quinnova Pharmaceuticals has launched Salvax (hydrating topical foam) Rx for the treatment of hyperkeratotic conditions such as  psoriasis, keratosis pilaris and xerosis.

Salvax contains 6% salicylic acid, a potent keratolytic agent,  formulated in a water-lipid based foam. The product utilizes Quinnova's  patented Proderm Technology, containing a unique combination of  physiological lipids, dimethicone and glycerin which together help to  restore the skin barrier, hydrate and protect the skin, in addition to  having anti-inflammatory properties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight